News and Comments

The Sky’s The Limit For Micromet’s BiTE Technology’s Capability

  Tuesday, July 19, 2011

Micromet (MITI) added another important collaborator, Amgen (AMGN), to a long list of large and small drug developing companies that are attracted to Micromet’s BiTE technology. Amgen/Micromet agreement looks fair for both. It fits Amgen’s strategy of focusing on adding next-generation products to its pipeline and helps Micromet’s financial requirements during the development of its promising proprietary cancer programs. Amgen wanted to select from among three BiTE-based drugs against three undisclosed solid tumor targets. The giant biotech will pay upfront, milestone, and other payments in a deal that could be worth over $900 million for the two selected drugs, or half of this amount if it selects only one drug, in addition to double-digit royalties in the event of approvals and sales. More...

Recent Postings



AGOS (ARGS) AERIE PHARMACEUTICALS Roche (ROCHE) Biogen Idec (BIIB) Vitae Pharmaceuticals (VTAE) Ziofpharm (ZIOP) Global Cell Therapeutics (GBT) KITE (KITE) ADVENTRIX (ANX) VANDA (VNDA) Intermune (ITMN) Idenix (IDIX) ARGOS (ARGS) Biocryst (BCRX) Anacor (ANAC) Telaprevir Vertex (VRTX) ZALTRAP™ Sanofi-Aventis (SAN) NOVOCURE (NVCR) Ariad (ARIA) Incyte (INCY) ISIS (ISIS) GUARDIAN HEALTH Rapamune SERES THERAPEUTICS (MCRB) Intrexon (XON) Gilead (GILD) Auspex (ASPX) CompuGen (CGEN) Sequenom (SQNM) Prolor Biotech (PBTH) Bristol-Myers Squibb (BMY) GlaxoSmithKline (GSK) Amgen (AMGN) Galena (GALE) Dendreon (DNDN) PTC Therapeutics (PTCT) SYNTA (SNTA) ARCA (ABIO) Agenus (AGEN Theravance (THRX) Revlimid (lenolidamide) Seattle Genetics (SGEN) Theravance Bio Pharma (TBPH) Velcade (bortezomib) Herceptin REGULUS (RGLS) Anadys (ANDS) JUNO (JUNO) Illumina (ILMN) IDERA (IDRA) Aimmune Therapeutics (AIMT) Sangamo (SGMO) Abbott Laboratories (ABT) Ridaforolimus ABBVIE (ABBV) Sanofi (SNA) Jazz Pharmaceuticals (JAZZ) BIOMARIN (BMRN) ImmunoGen (IMGN) RenenxBio (RGNX) Pluristem (PSTI) Alder Biopharmaceuticals (ALDR) Endometrial Cancer SUNESIS PHARMACEUTICALS (SNSS) Human Genome Sciences (HGSI) TOKAI (TKAOI) galapagos (GLPG) Zerenex Micromet (MITI) HALOZYME (HALO) Dynavax (DVAX) INNOVIVA (INVA) KERYX (KERX) OSI (OSIP) Benlysta (belimumab) Tysabri Onyx (ONXX) Trastuzumab-DM1 Alnylam (ALNY) Xoma (XOMA) Multiple Myeloma Intercept (ICPT) Merck (MRK) Roche (RHHBY) Genentech ACADIA (ACAD) Regeneron (REGN) Sanofi (SNY) Human Longevity (HLI) Mirati Therapeutics (MRTX) Agenus (AGEN) NANTKWEST (NK) Elan (ELN) Cytokinetics (CYTK) Spike Therapeutics (ONCE) NEKTAR (NKTR)) Array Pharmaceuticals (ARRY) Prosensa (RNA) Exelixis (EXEL) Inovio (INO) Ionis (IONS) C4 Therapeutics Valeant Pharmaceuticals International (VRX) Sarepta (SRPT) Editas (EDIT)